NCT05762393View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

November 17, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions

Schistosomiasis

Interventions

BIOLOGICAL

Sm-p80 + GLA-SE

Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.

Trial Locations (2)

Unknown

Groupe de Recherche Action en Santé (GRAS), Ouagadougou

Madagascar Institute for Vaccine Research (University of Antananarivo), Antananarivo

All Listed Sponsors

lead

International Vaccine Institute

OTHER

NCT05762393 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar | Biotech Hunter | Biotech Hunter